Wu TT, et al. - This research probed into the 5-year outcomes, efficacy, and safety of intravitreal ranibizumab injections for the treatment of myopic choroidal neovascularization. The findings illustrated the safety and efficacy of intravitreal ranibizumab for treating myopic choroidal neovascularization. Only 44% of eyes required retreatment after the first year. An improvement was achieved in the vision, in more than 60% of eyes over 5 years.